ONC Nurses Guide for Authors

Article

ONCOLOGY’s Nurse Edition publishes articles related to practical management issues in the care of patients with neoplastic disease. Through the Nurse Edition, ONCOLOGY aims to provide readers with useful insights into all aspects of patient management, with an emphasis on information and tools that can be applied to daily practice and patient education.

ONCOLOGY’s Nurse Edition publishes articles related to practical management issues in the care of patients with neoplastic disease. Through the Nurse Edition, ONCOLOGY aims to provide readers with useful insights into all aspects of patient management, with an emphasis on information and tools that can be applied to daily practice and patient education.

 

ONCOLOGY Nurse Edition is sent free of charge to about 15,000 oncology nurses, nurse practitioners, and physician assistants. ONCOLOGY is included in Medline, Excerpta Medica, EMBASE, and the Cancer Line and CancerLit databases at the National Cancer Institute.

 

Authorship credit is as outlined by the International Committee of Medical Journal Editors (ICMJE). Authors are persons who: (a) made substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data or manuscript; (b) drafted the article or revised it critically for important intellectual content; and (c) have final approval of the version to be published. Authorship signifies complete access to relevant data and control of the article content.

 

ONCOLOGY Nurse Edition will not consider articles that are sponsored directly or indirectly by a commercial entity (eg, a pharmaceutical company or public relations firm). Financial Disclosure statements are published for all authors and reviewers.

 

ONCOLOGY Nurse Edition does not publish original research articles.

 

REVIEW ARTICLES should focus on nursing management and intervention relevant to the topic discussed. They should include an abstract (of about 140 words) and a manuscript of about 3,500 words, including references. We suggest a limit of 25 references. Use of tables, charts, algorithms, and clinical illustrations or photographs is encouraged.

 

CASE STUDIES should be about 2,500 words in length and should include: patient overview, treatment summary, nurse management, outcome, discussion, and references. Please contact the Executive Editor, Anne Landry ( anne.landry@cmpmedica.com) for further guidance on these articles and on articles for other departments.

 

SPECIFICATIONS

• Manuscripts should be sub mitted via e-mail to anne.landry@cmpmedica.com or on CD-ROM to the address noted at the end of this guide. Most common file types are acceptable.
• Abbreviations should be explained in parentheses. In most cases, abbreviations should not be used.
• Drugs-Both generic and trade names should be given at first mention. Thereafter, only the generic name should be used.
• The title page should include the title, all authors’ names, their academic and clinical appointments, and
• their primary affiliations, city/state, any disclosures of financial relationships, and a telephone number and email address (for contact by our editors only).
• Digital images should be high resolution (300 dpi) and in .tif, .jpg, .eps, .pdf, or .ppt format. Tables, fi gures, and charts should be included with the manuscript document on individual pages.
• Copyright privileges, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Publisher. The Publisher will not refuse any reasonable request by the author(s) for permission to reproduce any of his or her contributions to the journal.
• Manuscripts and all accompanying material (on CD-ROM) can be mailed to:

 

ONCOLOGY Nurse Edition
Attn: Anne Landry
UBM Medica
600 Community Drive, 3rd floor
Manhasset, NY 11030

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content